Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Exclusive News
Aehr Test Systems: Small AI Stock Sees Record AI Hyperscaler OrderAuthor: Leo Miller. Publication Date: 4/22/2026. 
Key Points
- Aehr Test Systems just keeps winning AI orders, and shares are soaring
- The company's latest win is its largest to date, coming from a repeat hyperscaler customer
- Aehr is raising cash to fund growth, generating $60 million in gross proceeds from an equity issuance
- Special Report: Elon Musk’s $1 Quadrillion AI IPO
The small semiconductor stock Aehr Test Systems (NASDAQ: AEHR) is generating growing interest from customers and investors in 2026. Year-to-date, Aehr has soared more than 350%, making it one of the top performers in the U.S. stock market. Driving Aehr’s momentum is accelerating demand from artificial intelligence (AI) customers. Aehr’s two flagship products are its Sonoma and FOX-XP systems. These machines expose AI chips or wafers to extreme conditions to stress-test them and prevent faulty products from reaching data centers. As companies spend billions building AI infrastructure, Aehr’s equipment helps protect those investments.
For a moment…
Forget about Trump’s ties to Israel.
Forget about reports of Iran’s nuclear program.
Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. Click here to find out what it is.
After a string of orders, Aehr has just added its largest order yet. Hyperscaler Re-Ups on Sonoma With Record $41 Million OrderIn mid-April, Aehr said it received a record $41 million production order from its lead hyperscale customer. According to the company, “The order is the largest in Aehr’s history." The order is for the firm’s Sonoma systems; Sonoma tests chips after packaging, while FOX-XP tests at the earlier wafer level. This customer will use Sonoma to test its current-generation AI processor application-specific integrated circuits (ASICs), often called “custom silicon" or XPUs. Companies such as Broadcom (NASDAQ: AVGO) and Marvell Technology (NASDAQ: MRVL) co-develop these types of chips with massive hyperscalers like Meta Platforms (NASDAQ: META) or Amazon.com (NASDAQ: AMZN). Mentioning these names provides context for investors and is not intended to identify Aehr’s specific customers. Importantly, this is another follow-on order for the customer's current-generation chip testing needs. Aehr made similar announcements in July 2025 and August 2025, though the company did not disclose the sizes of those orders, suggesting they were more modest. That repeat business implies the customer sees clear value in Sonoma, and the latest $41 million order reflects a significant increase in their commitment. It further validates Aehr’s competitive position in the AI infrastructure market. Aehr’s Orders Shoot to Over $90 Million, Far Above Previous EstimatesAehr has also exceeded its order forecasts. The company had expected orders of $60 million to $80 million in the second half of fiscal 2026 (H2 FY2026). There are roughly five weeks left in Aehr’s FY2026, as its fiscal reporting period runs several quarters ahead of the calendar year. With the record Sonoma order, H2 FY2026 bookings have climbed to over $92 million — about 31% above the midpoint of prior guidance. Given the rapid cadence of recent announcements, that total could rise further. Aehr is also working with this customer on its next-generation AI processor ASIC. The company received an initial order for Sonoma systems for that device in February, and it expects the chip to move into production sometime in calendar 2026. “As these next-generation devices move into volume production, we see the potential for further substantial increases in demand for Sonoma systems and consumables in our next fiscal year,” the company said. Given the repeat orders for the current-generation device, continued follow-on demand for next-generation parts would not be surprising. Beyond the hyperscaler, Aehr is attracting interest from customers across data-center components, including a silicon photonics customer. Silicon photonics is a networking technology that enables high-speed communication between data-center components. The company says it is also engaging potential customers in flash memory and high-bandwidth memory. For context, flash memory players include firms like SanDisk (NASDAQ: SNDK), while Micron Technology (NASDAQ: MU) is a notable name in high-bandwidth memory. These examples are provided for reference and do not imply specific partnerships. Aehr Issues Shares, Adding Tens of Millions to Its Balance SheetRecently, Aehr issued a significant number of shares, generating gross proceeds of $60 million. While dilutive to existing shareholders, the raise substantially improves Aehr’s cash position; cash and equivalents were about $36.9 million at the end of the latest quarter. For a company experiencing a demand inflection, the capital infusion is largely positive. It suggests Aehr is funding production-capacity expansion to meet current orders and position itself for future demand. Overall, the combination of record orders and a stronger balance sheet positions Aehr to capitalize on AI-driven testing needs. Investors should watch how effectively the company scales production to fulfill orders and manage dilution as it grows. |
Post a Comment
Post a Comment